Human Review for AI-Assisted Healthcare Marketing
A review-intensity matrix for AI-assisted healthcare marketing based on potential harm, reversibility, and public exposure, with clear accountability.
The short answer
"Human in the loop" is a common phrase in AI governance. In practice, it often means someone glanced at the output. For healthcare marketing, where errors can mislead patients or clinicians, review needs to be specific: who reviews, what they check, and how much scrutiny each use deserves. A review-intensity matrix sets that level.
Three factors set review intensity
Potential harm. Could an error mislead someone about a health decision, expose private data, or violate regulations?
Reversibility. Can the error be caught and fixed before it matters? An internal draft is easy to fix. A published ad or an automated budget shift may not be.
Public exposure. Will patients, clinicians, or regulators see the output?
The review-intensity matrix
| Intensity | When | What review involves |
|---|---|---|
| Light | Low harm, easily reversible, internal | Author checks output before using it |
| Standard | Moderate harm or partner-facing | A second person reviews against a checklist |
| Full | High harm, hard to reverse, or public | Formal review by qualified experts, documented approval |
Promotional content always requires full review through the organization's medical, legal, and regulatory process, regardless of whether AI was used. The FDA's Office of Prescription Drug Promotion oversees prescription drug promotion.
What reviewers should check
For AI-assisted content:
- Accuracy. Are claims correct and supported?
- Completeness. Is required information, such as risk information, present?
- Invented content. Are there facts, citations, or quotations that do not exist?
- Tone and appropriateness. Is the content suitable for the audience?
- Data exposure. Does the output reveal anything it should not?
For AI-assisted decisions, such as optimization recommendations:
- Logic. Does the reasoning make sense?
- Data. Was it based on the right data?
- Side effects. Could it harm quality, compliance, or other goals?
See testing AI optimization recommendations.
Make reviewers accountable
- Name the reviewer for each use.
- Give reviewers time and authority to reject outputs.
- Record approvals.
- Tell reviewers when AI was involved, so they know to check for AI-typical errors like invented citations.
Avoid review fatigue
If reviewers see hundreds of AI outputs a day, quality drops. Limit volume, prioritize high-risk items, and use checklists to keep reviews focused.
Audit periodically
Sample reviewed outputs and check them again. If errors are getting through, adjust the process. The NIST AI Risk Management Framework emphasizes ongoing monitoring.
Practical takeaway
For each AI use on your team, set a review intensity using the three factors, name the reviewer, and write a short checklist. Audit a sample each quarter.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.